TREANDA
· Patent Litigation & Settlement History ↓
Current GenericRadar decision
FDA_DISCONTINUED; FDA DISC action month 2018-05
Patent estate
| Patent | Effective date | Official listing | TRUE_DS | DS grade | Claim classification / basis | PTE | PED | Family |
|---|---|---|---|---|---|---|---|---|
| 8791270 | 2026-01-12 | DP/U U-1542 | — | — | — | — | — | — |
| 8791270 | 2026-07-12 | — — | — | — | — | — | 2026-07-12 | — |
| 8791270 | 2026-07-12 | ORANGE_BOOK U-1542 | N | N | DP English description not available. | — | 2026-07-12 | — |
| 8445524 | 2029-03-26 | DS — | — | — | — | — | — | — |
| 8344006 | 2029-09-23 | DP/U U-1402 | — | — | — | — | — | — |
| 8445524 | 2029-09-26 | — — | — | — | — | — | 2029-09-26 | — |
| 8445524 | 2029-09-26 | ORANGE_BOOK — | N | N | DP English description not available. | — | 2029-09-26 | — |
| 8344006 | 2030-03-23 | — — | — | — | — | — | 2030-03-23 | — |
| 8344006 | 2030-03-23 | ORANGE_BOOK U-1402 | N | N | DP English description not available. | — | 2030-03-23 | — |
Regulatory exclusivity
| Code | Start date | End date | Scope | Entire product | All indications | Full coverage date | Combination | Source |
|---|---|---|---|---|---|---|---|---|
| ODE | 2008-03-20 | 2015-03-20 | CLL | N | N | — | Source | |
| PED | 2015-03-20 | 2015-09-20 | English description not available. | N | N | — | Source | |
| ODE | 2008-10-31 | 2015-10-31 | English description not available. | N | N | — | Source | |
| PED | 2015-10-31 | 2016-05-01 | English description not available. | N | N | — | Source | |
| ODE* | 2015-12-07 | 2022-12-07 | English description not available. | N | N | — | Source |
2026-10-10 · NO_RECORD_IN_CURRENT_SNAPSHOT · Historical coverage: NOT_COMPLETE
Generic approval evidence
| Application / product | Event | Final date | Tentative date | Applicant | Authorized generic | Exact mapping | Source |
|---|---|---|---|---|---|---|---|
| No generic approval facts are linked to this product. | |||||||
Market Entry Information
API filings, authorized generics and linked regulatory milestones.
API Master Files & Certifications 0 records
Ingredient-level registrations from linked public manufacturer portfolios. A filing does not establish supply to this finished product. DMFs are not FDA approvals.
| API | Holder / manufacturer | Holder country | Filing type | Number | Status | Filed date | Available for reference | Source | Last verified |
|---|---|---|---|---|---|---|---|---|---|
| No master-file or certification records are linked through public manufacturer portfolios. | |||||||||
Authorized Generics 0 records
Authorized generics are shown separately from independent ANDA approvals.
| Application / product | Applicant | Event / status | First marketed | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No authorized-generic records are linked to this product. | ||||||
Tentative ANDA Approvals 0 records
Tentative approval is not final approval. Historical tentative approvals remain visible after a linked final approval.
| Application / product | Applicant | Event / status | Tentative date | Follow-up final approval | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|---|
| No tentative-approval records are linked to this product. | |||||||
Paragraph IV Challenges 0 records
Paragraph IV challenges below are sourced from legal records separately from FDA approvals. An ANDA filing, lawsuit or settlement does not establish final approval or commercial launch.
| Application / product | Applicant | Event / status | Certification event date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No structured Paragraph IV certification events are linked in the available approval evidence. | ||||||
Final ANDA Approvals 0 records
Approval dates do not establish commercial launch. Product mapping is shown for each linked record.
| Application / product | Applicant | Event / status | Final approval date | Product mapping | Source | Last verified |
|---|---|---|---|---|---|---|
| No final-approval records are linked to this product. | ||||||
Decision evidence (9)
| Type | Date | Role | Basis | Source |
|---|---|---|---|---|
| PATENT | 2026-07-12 | HISTORICAL_CONTEXT | English description not available. | Source |
| PATENT | 2029-09-26 | HISTORICAL_CONTEXT | English description not available. | Source |
| PATENT | 2030-03-23 | HISTORICAL_CONTEXT | English description not available. | Source |
| REGULATORY_EXCLUSIVITY | — | HISTORICAL_CONTEXT | CLL | Source |
| REGULATORY_EXCLUSIVITY | — | HISTORICAL_CONTEXT | English description not available. | Source |
| REGULATORY_EXCLUSIVITY | — | HISTORICAL_CONTEXT | English description not available. | Source |
| REGULATORY_EXCLUSIVITY | — | HISTORICAL_CONTEXT | English description not available. | Source |
| REGULATORY_EXCLUSIVITY | — | HISTORICAL_CONTEXT | English description not available. | Source |
| REGULATORY_STATUS | — | TERMINAL_STATUS | FDA_DISCONTINUED; FDA DISC action month 2018-05 | Source |
Litigation & Settlement History
Settlement launch rights generally apply only to the named parties and product scope. These records do not change GenericRadar patent/exclusivity anchors or current decisions.
| Event date | Party | Event | Licensed entry | Evidence | Source |
|---|---|---|---|---|---|
| Not disclosed | Multiple ANDA / 505(b)(2) applicants | SETTLEMENT Brand-level record; strength scope not established
|
2027-11-17 | REVIEW | — |
| Historic settlements; split separate counterparties | |||||